Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s823
DOI: 10.25251/3ggsk832 ↗Abstract
Introduction: Microcystic lymphatic malformations (mLM) are lifelong, rare, and serious vascular anomalies associated with substantial physical and psychosocial morbidity. Currently, no FDA-approved therapeutics exist; disease management involves invasive procedures (surgery, sclerotherapy, laser) and off-label oral and topical sirolimus, all associated with inconsistent results. Sirolimus topical gel 3.9%, developed on the QTORIN™ platform to address these unmet therapeutic needs, was evaluated in the pivotal Phase 3 SELVA trial. Consistent with regulatory guidance emphasizing the patient voice in drug development, an embedded qualitative interview study characterized patient/caregiver perspectives of mLM and the meaningfulness of treatment-related change. Objective: To contextualize clinical trial efficacy endpoints through the patient/caregiver experience and evaluate treatment satisfaction following topical sirolimus 3.9% gel. Methods: Semi-structured entry (baseline) and exit (Day 168) interviews were conducted with trial participants and/or their caregivers (for participants
EUVIMED